a direct causal link in humans has not been established, and current EU and UK summaries of product characteristics (SmPCs) for approved GLP-1-based therapies do not list this as a formal contraindication, though it remains a theoretical concern warranting caution People with severe gastrointestinal conditions , such as gastroparesis or inflammatory bowel disease Those with a history of pancreatitis , which has been associated with GLP-1 receptor agonist use Children and young people under 18 , who have not been studied in retatrutide trials to date People with a history of gallbladder disease or gallstones , given the known association between this drug class and gallbladder events Those with proliferative diabetic retinopathy or macular oedema , where rapid improvements in blood glucose control may carry additional risks People with severe renal or hepatic impairment , pending further safety data Age-related eligibility, renal function, hepatic status, and existing medications would all need to be carefully assessed by a qualified clinician before any treatment decision could be made
Altered GI motility and changes in bile acid metabolism can cause loose stools, particularly during titration
many people could benefit from both GLP as well as surgery
In case you miss your Wegovy dose for more than 2 weeks, take the next dose on the scheduled day or talk to your healthcare provider for medical advice
In a mouse myocardial ischemia model, thymosin beta-4 was shown to activate integrin-linked kinase (ILK), promoting cardiomyocyte migration and survival
